CLDX News and Press, Celldex Therapeutics Inc. From 05/04/25

2025-05-04 18:43:27 ET Celldex Therapeutics, Inc. (CLDX) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CLDX stock price following earnings has averaged ±1.18% , with a median of 0.92...

2025-04-22 07:40:22 ET Summary We initiate a Hold rating for Celldex Therapeutics due to uncertainties surrounding barzolvolimab's mid-2025 data readouts and potential market positioning challenges. Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic induc...

2025-03-20 11:44:08 ET More on Celldex Celldex Therapeutics: Will They Get It Right After A Decade Of Failures? Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial information for Celldex Read the full artic...

2025-03-05 15:13:52 ET Emerging Biotech Firms Offer Key Insights into Growth Potential The %Biotechnology sector continues to attract investor interest as companies push forward with innovative treatments and breakthrough therapies. Two emerging biotech firms, %CelldexTherapeu...

- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel ...

2025-03-02 08:00:41 ET As Wall Street steps into March, the earnings schedule offers a look at how a broad range of industries are navigating the current economic landscape.... Read the full article on Seeking Alpha For further details see: Earnings week ahead: TGT, COST, CR...

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on t...

2025-02-27 16:45:01 ET More on Celldex Celldex Therapeutics: Will They Get It Right After A Decade Of Failures? Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial information for Celldex Read the full artic...

Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development Phase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in Phase 2 PN study Celldex’s first bispecific for inflammator...

Grupo Aeroportuario del Sureste S.A. de C.V. (ASR) is expected to report $5.54 for Q4 2024 Zoom Communications Inc. (ZM) is expected to report $0.66 for Q4 2025 Toro Corp. (TORO) is expected to report for Q4 2024 Apple Hospitality REIT Inc. (APLE) is expected to report $0.31 for Q4 20...